Previous 10 | Next 10 |
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. ...
2024-03-26 14:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-15 11:30:03 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for VIR on March 15, 2024 10:00AM ET. The previous analyst recommendation was Underperform. VIR was trading at $10.54 at issue of the analyst recommendation. The overall analyst consensus :...
2024-03-15 11:30:03 ET J.P. Morgan analyst issues BUY recommendation for VIR on March 15, 2024 10:00AM ET. The previous analyst recommendation was Buy. VIR was trading at $10.54 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...
2024-03-13 11:07:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interes...
– Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter – – Approximately 50% of participants have compensated cirrhosis – Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clin...
2024-02-26 06:55:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It’s also fairly easy to identify such sto...
2024-02-23 10:00:17 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming UBS concedes it wasn't bullis...
2024-02-22 20:49:13 ET More on etc. Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript Hooker Furnishings: Temporary Headwinds Haven't Created An Attractive Buying Level MP Materials Corp. (MP) Q4 2023 Earnings Call Transcript Crude oil edges high...
2024-02-22 20:48:06 ET Vir Biotechnology, Inc. (VIR) Q4 2023 Results Conference Call February 22, 2024 04:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Ph...
News, Short Squeeze, Breakout and More Instantly...
Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people living with chronic hepatitis delta Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that ...
2024-06-05 19:15:02 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for VIR on June 5, 2024 05:15PM ET. The previous analyst recommendation was Equal-Weight. VIR was trading at $12.66 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-05 17:00:05 ET Michael Ulz from Morgan Stanley issued a price target of $15.00 for VIR on 2024-06-05 14:37:00. The adjusted price target was set to $15.00. At the time of the announcement, VIR was trading at $12.66. The overall price target consensus is at $30.13...